Clinical efficacy and emerging therapeutic utilization of novel taxanes

European Journal of Cancer, Supplement

Volumn 6, Issue 10, 2008, Pages 12-21

  Gradishar, William ^a   Cortes, Javier ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Bevacizumab; Breast cancer; Capecitabine; Carboplatin; Docetaxel; Gemcitabine; Nab paclitaxel; Paclitaxel; Taxane

Indexed keywords

ANTHRACYCLINE; ANTIHISTAMINIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CREL PACLITAXEL; CREMOPHOR; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; NAB PACLITAXEL; PACLITAXEL; POLYSORBATE 80; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SORAFENIB; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOVASCULAR DISEASE; COMBINATION CHEMOTHERAPY; DEATH; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEADACHE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; LEUKOPENIA; LOW DRUG DOSE; LUNG CANCER; MELANOMA; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSTATE CANCER; RASH; SENSORY NEUROPATHY; SIDE EFFECT; SOLVENT EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 50949134126     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(08)71922-0     Document Type: Article

References (55)

1. Ringel I., and Horwitz S.B. Studies with RP 56976 (Taxotere): a semisynthetic analogue of Taxol. J Natl Cancer Inst 83 (1991) 288-291
2. van Zuylen L., Verweij J., and Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs 19 (2001) 125-141
3. Adams J.D., Fiora K.P., Goldspiel B.R., et al. Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst Monogr 15 (1993) 141-147
4. Ellis A.G., Crinis N.A., and Webster L.K. Inhibition of etoposide elimination in the isolated perfused rate liver by Cremophor EL and Tween 80. Cancer Chemother Pharmacol 38 (1996) 81-87
5. ten Tije A.J., Verweij J., Loos W.J., et al. Pharmacological effects of formulation vehicles. Implications for cancer chemotherapy. Clin Pharmacokinet 42 (2003) 665-685
6. Eisenhauer E.A., and Trudeau M. An overview of phase II studies of docetaxel in patients with metastatic breast cancer. Eur J Cancer 31A Suppl 4 (1995) S11-S13
7. Gelderblom H., Verweij J., Nooter K., et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37 (2001) 1590-1598
8. Szebeni J., Muggia F.M., and Alving C.R. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 90 (1998) 300-306
9. TAXOL® (paclitaxel) INJECTION [prescribing information] (2007), Bristol-Myers Squibb Company, Princeton, NJ
10. TAXOTERE® (docetaxel) Injection Concentrate [prescribing information] (2007), Sanofi aventis U.S. LLC, Bridgewater, NJ
11. Harries M., Ellis P., and Harper P. Nanoparticle albumin-bound paclitaxel for metastatic breast cancer. J Clin Oncol 23 (2005) 7768-7771
12. Wolff A.C., Donehower R.C., Carducci M.K., et al. Phase I study of docosahexaenoic acid tocixity profile. Clin Cancer Res 9 (2003) 589-597
13. Kim T.Y., Kim D.W., Chung J.Y., et al. Phase I and pharmacokinetic study of Genexol-PM, a Cremophor-free, polymeric micelle formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 10 (2004) 3708-3716
14. Hidalgo M., Aylesworth C., Hammond L.A., et al. Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel. J Clin Oncol 19 (2001) 2493-2503
15. Sessa C., Curvier C., Caldiera S., et al. Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors. Ann Oncol 13 (2002) 1140-1150
16. Kurata T., Shimada Y., Tamura T., et al. Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1 hour intravenous infusion in patients with advanced solid tumors. J Clin Oncol 19 (2000) 3164-3171
17. Maeda H., Wu J., Sawa T., et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65 (2000) 271-284
18. Desai N., Trieu V., Yao Z., et al. Increased antitumor activity, intratumoral paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12 (2006) 1317-1324
19. Gradishar W.J., Tjulandin S., Davidson N., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23 (2005) 7794-7803
20. Guan Z., Feng F., Li Q.L., et al. Randomized study comparing nab-paclitaxel with solvent-based paclitaxel in Chinese patients (pts) with metastatic breast cancer (MBC). J Clin Oncol 25 18S part I (2007) 1038 [abstract].
21. Blum J.L., Savin M.A., Edelman G., et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 7 (2007) 850-856
22. Gradishar W., Krasnojon D., Cheporov S., et al. Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC). J Clin Oncol 25 18S part I (2007) 1032 [abstract].
23. Schwartzberg L.S., Arena F., Mintzer D., et al. Phase II trial of nanoparticle albumin-bound paclitaxel (ABX) + capecitabine (XEL) in first line treatment of metastatic breast cancer (MBC): interim results. Breast Cancer Res Treat 100 Suppl 1 (2006) 1096 [abstract].
24. Somer B.G., Schwartzberg L.S., Arena F., et al. Phase II trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel (ABX)) + capecitabine (XEL) in first-line treatment of metastatic breast cancer (MBC). J Clin Oncol 25 18S part I (2007) 1053 [abstract].
25. Roy V., LaPlant B.R., Gross G.G., et al., the North Central Cancer Treatment Group. NCCTG phase II trial N0531 of weekly nab-paclitaxel (nab-p) in combination with gemcitabine (gem) in patients with metastatic breast cancer (MBC). J Clin Oncol 25 18S part I (2007) 1048 [abstract].
26. Trieu V., Ran S., Bivens C., et al. Chemoprotection by VEGF: Rationale for combination nab-paclitaxel and bevacizumab. J Clin Oncol 25 18S part I (2007) 1064 [abstract].
27. Ran S., Volk L., Bivens C., et al. Combination of nab-paclitaxel and bevacizumab eradicates well-established tumors as well as lymphatic and pulmonary metastases in a MDA-MB-231 model of a highly metastatic human breast cancer. Breast Cancer Res Treat 106 Suppl 1 (2007) 74 [abstract].
28. Link J.S., Waisman J.R., and Jacobs C.I. Bevacizumab (Avastin) and albumin bound paclitaxel (Abraxane) treatment in metastatic breast cancer. Breast Cancer Res Treat 100 Suppl 1 (2006) 1095 [abstract].
29. Link J.S., Waisman J.R., Nguyen B., et al. Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer. Clin Breast Cancer 7 (2007) 779-783
30. Conlin A.K., Seidman A.D., Moynahan M.E., et al. Randomized phase II trial of three dosing schedules of nanoparticle albumin-bound paclitaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer: An initial interim safety report. J Clin Oncol 25 18S part I (2007) 1104 [abstract].
31. ClinicalTrials.gov. Open studies of nab-paclitaxel and chemotherapy and metastatic breast cancer. Bethesda, MD: US National Institute of Health; [cited 2008 May 1]. Available at http://clinicaltrials.gov/ct2/results?flds=Xj&flds=a&flds=b& term=paclitaxel+AND+chemotherapy+AND+metastatic+breast+cancer&recr=O pen&show_flds=Y.
32. Robidoux A., Buyse M., Buzdar A., et al. Neoadjuvant chemotherapy with sequential weekly nanoparticle albumin-bound paclitaxel (ABI-007, Abraxane®) followed by 5-fluorouracil, epirubicin and cyclophosphamide (FEC) in locally advanced breast cancer (LABC): a phase II trial of the NSABP Foundation research programs (FRP). Breast Cancer Res Treat 100 Suppl 1 (2006) 3068 [abstract].
33. Somlo G., Paz B., Shen J., et al. A randomized phase II neoadjuvant trial in patients with stage II-III and inflammatory breast cancer. Breast Cancer Res Treat 106 (2007) 5073 [abstract].
34. Daniel B.R., Doss H., Gian V., et al. Biweekly neoadjuvant gemcitabine, epirubicin, and nano-particle albumin bound (nab) paclitaxel (GEA) with tumor SPARC analysis correlated with pathologic responses: Results of a multicenter phase II trial. J Clin Oncol 25 18S part I (2007) 11060 [abstract].
35. Robert N., Ambro S., Krekow L., et al. Pilot study of dose dense doxorubicin + cyclophosphamide followed by ABI-007 in patients with early stage breast cancer. Breast Cancer Res Treat 94 Suppl 1 (2005) S109
36. Burstein H.J., Mayer E.L., Peppercorn J., et al. Dosedense nab-paclitaxel (nanoparticle albumin-bound paclitaxel) in adjuvant chemotherapy for breast cancer: A feasibility study. J Clin Oncol 25 18S part I (2007) 594 [abstract].
37. McArthur H.L., Rugo H., Paulson M., et al. Cardiac safety of adjuvant bevacizumab plus dose-dense doxorubicin/cyclophosphamide followed by nanoparticle albumin-bound paclitaxel in patients with early stage breast cancer. Breast Cancer Res Treat 106 Suppl 1 (2007) S147
38. ClinicalTrials.gov. Study of dose-dense Adriamycin plus Cytoxan (AC) followed by either Abraxane or Taxol with bevacizumab as adjuvant therapy for patients with breast cancer. Bethesda, MD: US National Institute of Health; [updated 2008 June 6; cited 2008 May 1]. Available at http://clinicaltrials.gov/ct2/show/NCT00394251?term=NCT00394251&rank =1.
39. Green M.R., Manikhas G.M., Orlov S., et al. Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 17 (2006) 1263-1268
40. Allerton J.P., Hagenstad C.T., Webb R.T., et al., the Online Collaborative Oncology Group. A phase II evaluation of the combination of paclitaxel protein-bound and carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC). J Clin Oncol 24 18S part I (2006) 7127 [abstract].
41. Greco FA, Allerton JP, Hagenstad CT, et al. Albumin bound paclitaxel wkly+carboplatin: first-line therapy for advanced NSCLC. Presented at: Chemotherapy Foundation Symposium XXIV; November 8-11, 2006; New York, NY.
42. Reynolds C., Barrera D., Vu D.Q., et al. An open-label, phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab in first-line patients with advanced non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol 25 18S part I (2007) 7610 [abstract].
43. Rizvi N.A., Riely G.J., Azzoli C.G., et al. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non- small-cell lung cancer. J Clin Oncol 26 (2008) 639-643
44. Hawkins M.J., Georgy M., Makhson A., et al. Dose escalation study of nab-paclitaxel followed by carboplatin as first line therapy in advanced non-small lung cancer (NSCLC). J Clin Oncol 24 18S part I (2006) 7132 [abstract].
45. Hawkins M.J., Manikhas G., Makhson A., et al. Study of three weekly nab-paclitaxel regimens in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 25 18S part I (2007) 7659 [abstract].
46. ClinicalTrials.gov. Open studies of paclitaxel and lung cancer. Bethesda, MD: US National Institute of Health; [cited 2008 May 1]. Available at http://www.clinicaltrials.gov/ct2/results?flds=Xj&flds=a&flds=b &term=paclitaxel+and+lung+cancer&recr=Open&show_flds=Y.
47. Hersh E.M., O'Day S., Gonzalez R., et al. Open-label, multicenter, Phase II trial of ABI-007 in previously treated and previously untreated patients with metastatic malignant melanoma. J Clin Oncol 23 16S part I (2005) 7558 [abstract].
48. Abraxis Oncology. Research & development: clinical trials. Bridgewater, NJ: Abraxis BioScience, LLC; [cited 2008 June 10]. Available at http://abraxisoncology.com/rnd_trials.aspx.
49. Teneriello M.G., Tseng P.C., Crozier M., et al. Results of a phase II evaluation of nanoparticle albumin bound paclitaxel (nab-paclitaxel) in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol 25 18S part I (2007) 5525 [abstract].
50. ClinicalTrials.gov. Open studies of paclitaxel and prostate cancer. Bethesda, MD: US National Institute of Health; [cited 2008 May 1]. Available at http://www.clinicaltrials.gov/ct2/results?term=paclitaxel+and+prostate+c ancer&recr=Open&show_flds=Y&flds=Xabj.
51. ClinicalTrials.gov. Open studies of paclitaxel and pancreatic cancer. Bethesda, MD: US National Institute of Health; [cited 2008 May 1]. Available at http://www.clinicaltrials.gov/ct2/results?term=paclitaxel+and+pancreatic +cancer&recr=Open&show_flds=Y&flds=Xabj.
52. Von Hoff DD, Borad M, Ramanathan RK, et al. Promising clinical activity of a NAB paclitaxel plus gemcitabine combination in a disease-specific phase I trial of patients with advanced pancreatic cancer. Presented at: American Association for Cancer Research; April 12-16, 2008; San Diego, CA. Abstract 4179.
53. Ko A.H., Hwang A.P., Venook A.P., et al. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer 93 (2005) 195-199
54. Park B.B., Park J.O., Lee H.R., et al. A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 60 (2007) 489-494
55. Boeck S., Stieber P., Holdenrieder S., et al. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology 70 (2006) 255-264